These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 14599854

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E, Buggage RR.
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
    Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS.
    Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634
    [Abstract] [Full Text] [Related]

  • 9. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT.
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [Abstract] [Full Text] [Related]

  • 10. SOCS5 mRNA levels in peripheral blood mononuclear cells (PBMC): a potential bio-marker for monitoring response of uveitis patients to Daclizumab therapy.
    Egwuagu CE, Yu CR, Li Z, Nussenblatt RB.
    J Autoimmun; 2005 Feb; 24(1):39-46. PubMed ID: 15725575
    [Abstract] [Full Text] [Related]

  • 11. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
    Waldmann TA.
    J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565
    [Abstract] [Full Text] [Related]

  • 12. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.
    Sen HN, Levy-Clarke G, Faia LJ, Li Z, Yeh S, Barron KS, Ryan JG, Hammel K, Nussenblatt RB.
    Am J Ophthalmol; 2009 Nov; 148(5):696-703.e1. PubMed ID: 19664754
    [Abstract] [Full Text] [Related]

  • 13. Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab.
    ter Meulen CG, Göertz JH, Klasen IS, Verweij CM, Hilbrands LB, Wetzels JF, Hoitsma AJ.
    Kidney Int; 2003 Aug; 64(2):697-703. PubMed ID: 12846768
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
    Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X, Cohan S, Umans K, Greenberg SJ, Ozen G, Elkins J.
    BMC Neurol; 2016 Jul 26; 16():117. PubMed ID: 27461166
    [Abstract] [Full Text] [Related]

  • 16. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
    Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.
    Arch Neurol; 2009 Apr 26; 66(4):483-9. PubMed ID: 19364933
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children.
    Savo AM, Book BK, Henson S, Hakimi J, Pescovitz MD.
    Transplant Proc; 1999 Apr 26; 31(1-2):1182-3. PubMed ID: 10083528
    [No Abstract] [Full Text] [Related]

  • 19. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.
    Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, Vexler V, Shames RS, Daclizumab Asthma Study Group.
    Am J Respir Crit Care Med; 2008 Nov 15; 178(10):1002-8. PubMed ID: 18787222
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.